b '
<?xml version="1.0" ?>\n
<!DOCTYPE PubmedArticleSet
    PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
\n<PubmedArticleSet>\n<PubmedArticle>
        <MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated">
            <PMID Version="1">37391059</PMID>
            <DateRevised>
                <Year>2023</Year>
                <Month>06</Month>
                <Day>30</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1542-7714</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <PubDate>
                            <Year>2023</Year>
                            <Month>Jun</Month>
                            <Day>28</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Clinical gastroenterology and hepatology : the official clinical practice journal of the
                        American Gastroenterological Association</Title>
                    <ISOAbbreviation>Clin Gastroenterol Hepatol</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but
                    Similar Outcomes as Early Responders.</ArticleTitle>
                <ELocationID EIdType="pii" ValidYN="Y">S1542-3565(23)00496-2</ELocationID>
                <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cgh.2023.06.011</ELocationID>
                <Abstract>
                    <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Differences in one-year outcomes among
                        early compared to delayed responders to vedolizumab have been demonstrated in ulcerative
                        colitis. However, it is unclear whether similar differences exist with ustekinumab, and what
                        factors differentiate delayed responders from non-responders.</AbstractText>
                    <AbstractText Label="METHODS" NlmCategory="METHODS">This was a post-hoc analysis of patient-level
                        data from the UNIFI clinical trial. Ustekinumab-treated patients with clinical response, defined
                        as reduction in total Mayo score &#x2265;30% and &#x2265;3 points from baseline with reduction
                        in rectal bleeding subscore (RBS)&#x2265;1 or RBS&#x2264;1, at week 8 were deemed early
                        responders and their outcomes were compared with delayed responders (week 8 non-responders who
                        subsequently responded at week 16). The primary outcome assessed was one-year clinical remission
                        (CR), defined as total Mayo score &#x2264;2 and no subscore &gt;1.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 642 ustekinumab-treated patients,
                        including 321 (50%) early responders, 115 (17.9%) delayed responders, and 205 (32.1%)
                        non-responders. No differences were observed for one-year CR among early vs. delayed responders
                        [132/321 (41.1%) vs. 40/115 (34.8%), p=0.233], nor for other outcomes assessed regardless of
                        induction dose. Compared to early responders, delayed responders had more severe baseline Mayo
                        endoscopic disease [88/115 (76.5%) vs. 206/321 (64.2%), p=0.015] and abnormal baseline CRP
                        &gt;3mg/L [83/115 (72.2%) vs. 183/321 (57%), p=0.004]. Compared to non-responders, delayed
                        responders had a significant decline in CRP (F(4, 844), p&lt;0.0001) and fecal calprotectin
                        (F(4, 818), p&lt;0.0001) through week 16.</AbstractText>
                    <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared with early ustekinumab
                        responders, delayed responders had greater inflammatory burden at baseline. Early and delayed
                        responders have similar one-year outcomes. Biomarker decline observed in delayed responders can
                        help differentiate them from non-responders.</AbstractText>
                    <CopyrightInformation>Copyright &#xa9; 2023 AGA Institute. Published by Elsevier Inc. All rights
                        reserved.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Wong</LastName>
                        <ForeName>Emily C L</ForeName>
                        <Initials>ECL</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Medicine (Division of Gastroenterology) and Farncombe Family
                                Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
                            </Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Dulai</LastName>
                        <ForeName>Parambir S</ForeName>
                        <Initials>PS</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Gastroenterology, Northwestern University, Chicago, IL, USA.
                            </Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Marshall</LastName>
                        <ForeName>John K</ForeName>
                        <Initials>JK</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Medicine (Division of Gastroenterology) and Farncombe Family
                                Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
                            </Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Jairath</LastName>
                        <ForeName>Vipul</ForeName>
                        <Initials>V</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Medicine, Division of Gastroenterology, Western University,
                                London, ON, Canada.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Reinisch</LastName>
                        <ForeName>Walter</ForeName>
                        <Initials>W</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Internal Medicine III, Division of Gastroenterology and
                                Hepatology, Medical University of Vienna, W&#xe4;hringer G&#xfc;rtel 18-20, Vienna,
                                Austria.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Narula</LastName>
                        <ForeName>Neeraj</ForeName>
                        <Initials>N</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Medicine (Division of Gastroenterology) and Farncombe Family
                                Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
                                Electronic address: Neeraj.narula@medportal.ca.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2023</Year>
                    <Month>06</Month>
                    <Day>28</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>United States</Country>
                <MedlineTA>Clin Gastroenterol Hepatol</MedlineTA>
                <NlmUniqueID>101160775</NlmUniqueID>
                <ISSNLinking>1542-3565</ISSNLinking>
            </MedlineJournalInfo>
            <CitationSubset>IM</CitationSubset>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">Endoscopic Improvement</Keyword>
                <Keyword MajorTopicYN="N">Inflammatory Bowel Disease</Keyword>
                <Keyword MajorTopicYN="N">Ulcerative Colitis</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2022</Year>
                    <Month>12</Month>
                    <Day>21</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="revised">
                    <Year>2023</Year>
                    <Month>6</Month>
                    <Day>2</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2023</Year>
                    <Month>6</Month>
                    <Day>12</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2023</Year>
                    <Month>7</Month>
                    <Day>1</Day>
                    <Hour>11</Hour>
                    <Minute>41</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2023</Year>
                    <Month>7</Month>
                    <Day>1</Day>
                    <Hour>11</Hour>
                    <Minute>41</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2023</Year>
                    <Month>6</Month>
                    <Day>30</Day>
                    <Hour>19</Hour>
                    <Minute>16</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>aheadofprint</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">37391059</ArticleId>
                <ArticleId IdType="doi">10.1016/j.cgh.2023.06.011</ArticleId>
                <ArticleId IdType="pii">S1542-3565(23)00496-2</ArticleId>
            </ArticleIdList>
        </PubmedData>
    </PubmedArticle>
</PubmedArticleSet>'